Runben Biotechnology Co., Ltd. (SHA:603193)
China · Delayed Price · Currency is CNY 17.10
-0.23 (-1.33%)
Oct 29, 2026, 3:00 PM CST
Runben Biotechnology Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,712 | 1,544 | 1,317 | 1,032 | 855.65 | 581.91 |
Other Revenue | 0.96 | 0.96 | 0.77 | 0.66 | 0.44 | 0.24 |
| 1,713 | 1,545 | 1,318 | 1,033 | 856.09 | 582.15 | |
Revenue Growth | 12.86% | 17.19% | 27.61% | 20.66% | 47.06% | 31.46% |
Cost of Revenue | 683.85 | 646.61 | 553.2 | 453.34 | 393.28 | 275.75 |
Gross Profit | 1,030 | 898.19 | 764.98 | 579.62 | 462.81 | 306.4 |
Selling, General & Admin | 604.65 | 521.03 | 411.86 | 301.68 | 257.21 | 155.39 |
Research & Development | 40.18 | 37.59 | 35.07 | 25.69 | 19.51 | 13.6 |
Other Operating Expenses | 15.82 | 11.45 | 14.49 | 9.42 | 8.77 | 6.83 |
Operating Expenses | 660.75 | 570.31 | 461.89 | 336.99 | 285.47 | 175.82 |
Operating Income | 368.85 | 327.87 | 303.08 | 242.62 | 177.34 | 130.58 |
Interest Expense | -0.04 | -0.08 | -0.13 | -0.26 | -0.43 | -0.54 |
Interest & Investment Income | 21.82 | 30.56 | 34.84 | 16.4 | 7.18 | 6.09 |
Currency Exchange Gain (Loss) | 0.05 | 0.05 | 0 | - | - | 0.24 |
Other Non Operating Income (Expenses) | -0.7 | -0.17 | -0.14 | -0.05 | -0.16 | -0.05 |
EBT Excluding Unusual Items | 389.98 | 358.23 | 337.66 | 258.72 | 183.94 | 136.32 |
Gain (Loss) on Sale of Investments | 3.5 | 0.84 | 3.59 | - | - | - |
Gain (Loss) on Sale of Assets | -0 | 0.08 | -0.6 | 0.07 | 0.05 | 0 |
Asset Writedown | -1.06 | - | - | - | - | - |
Other Unusual Items | 3.1 | 3.1 | 11.36 | 9.13 | 4.29 | 5.31 |
Pretax Income | 395.52 | 362.25 | 352 | 267.93 | 188.27 | 141.63 |
Income Tax Expense | 46.97 | 47.75 | 51.84 | 41.9 | 28.23 | 20.98 |
Net Income | 348.54 | 314.5 | 300.16 | 226.03 | 160.04 | 120.65 |
Net Income to Common | 348.54 | 314.5 | 300.16 | 226.03 | 160.04 | 120.65 |
Net Income Growth | 14.15% | 4.78% | 32.80% | 41.23% | 32.66% | 27.38% |
Shares Outstanding (Basic) | 405 | 403 | 406 | 353 | 341 | 335 |
Shares Outstanding (Diluted) | 405 | 403 | 406 | 353 | 341 | 335 |
Shares Change | 0.69% | -0.60% | 14.85% | 3.71% | 1.61% | 9.69% |
EPS (Basic) | 0.86 | 0.78 | 0.74 | 0.64 | 0.47 | 0.36 |
EPS (Diluted) | 0.86 | 0.78 | 0.74 | 0.64 | 0.47 | 0.36 |
EPS Growth | 13.37% | 5.41% | 15.63% | 36.17% | 30.56% | 16.13% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 219.16 | 187.42 | 183.02 | 238.87 | 124.67 | -13.38 |
Free Cash Flow Per Share | 0.54 | 0.47 | 0.45 | 0.68 | 0.37 | -0.04 |
Dividend Per Share | 0.540 | 0.460 | 0.410 | 0.170 | - | - |
Dividend Growth | 25.58% | 12.20% | 141.18% | - | - | - |
Gross Margin | 60.09% | 58.14% | 58.03% | 56.11% | 54.06% | 52.63% |
Operating Margin | 21.53% | 21.22% | 22.99% | 23.49% | 20.71% | 22.43% |
Profit Margin | 20.34% | 20.36% | 22.77% | 21.88% | 18.70% | 20.72% |
Free Cash Flow Margin | 12.79% | 12.13% | 13.88% | 23.13% | 14.56% | -2.30% |
EBITDA | 389.94 | 348.43 | 322.92 | 262.46 | 194.59 | 138.59 |
EBITDA Margin | 22.76% | 22.55% | 24.50% | 25.41% | 22.73% | 23.81% |
D&A For EBITDA | 21.09 | 20.55 | 19.84 | 19.84 | 17.25 | 8.01 |
EBIT | 368.85 | 327.87 | 303.08 | 242.62 | 177.34 | 130.58 |
EBIT Margin | 21.53% | 21.22% | 22.99% | 23.49% | 20.71% | 22.43% |
Effective Tax Rate | 11.88% | 13.18% | 14.73% | 15.64% | 14.99% | 14.82% |
Revenue as Reported | 1,713 | 1,545 | 1,318 | 1,033 | 856.09 | 582.15 |
Advertising Expenses | - | 419.37 | 320.61 | 218.47 | 187.47 | 107.9 |